A number of common eye diseases such as age-related macular degeneration and glaucoma are associated with ocular perfusion abnormalities. Although this is well recognized there is not much possibility to improve blood flow to the posterior pole of the eye in these diseases. For many years, moxaverine has been used in the therapy of perfusion abnormalities in the brain, the heart and the extremities. This is based on a direct vasodilatatory effect of the drug, but also on the rheological properties of red blood cells. In a recent study the investigators have shown that intravenous moxaverine increases choroidal blood flow in healthy young subjects. The present study aims to investigate, whether moxaverine also improves blood flow in the diseased eye after systemic administration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria
Choroidal and optic nerve head blood flow
Time frame: 2 hours
Retrobulbar flow velocities
Time frame: 2 hours
Retinal blood flow velocity
Time frame: 2 hours
Retinal venous and arterial diameters
Time frame: 2 hours
Intraocular pressure
Time frame: 2 hours
Systolic and diastolic blood pressure
Time frame: 2 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.